UY29505A1 - Forma cristalina de 1-cloro-4-(b(beta)-d-glucopiranos-1-il)-2-(4-((s)-tetrahidrofuran-3-iloxi)-bencil)-benceno, un método para su preparación y el uso del mismo para preparar medicamentos. - Google Patents

Forma cristalina de 1-cloro-4-(b(beta)-d-glucopiranos-1-il)-2-(4-((s)-tetrahidrofuran-3-iloxi)-bencil)-benceno, un método para su preparación y el uso del mismo para preparar medicamentos.

Info

Publication number
UY29505A1
UY29505A1 UY29505A UY29505A UY29505A1 UY 29505 A1 UY29505 A1 UY 29505A1 UY 29505 A UY29505 A UY 29505A UY 29505 A UY29505 A UY 29505A UY 29505 A1 UY29505 A1 UY 29505A1
Authority
UY
Uruguay
Prior art keywords
beta
benzene
preparation
same
glucopiranos
Prior art date
Application number
UY29505A
Other languages
English (en)
Inventor
Frank Himmelsbach
Sandra Schmid
Martin Schuehle
Hans-Jurgen Martin
Mattias Eckhardt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36593171&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29505(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY29505A1 publication Critical patent/UY29505A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals

Abstract

La invención se refiere a una forma cristalina de 1-cloro-4-(B(beta)-D-glucopiranos-1-il)-2-(4-((S)-tetrahidrofuran-3-iloxi)-bencil)-benceno, a un método para la preparación de la misma, así como al uso de la misma para preparar medicamentos.
UY29505A 2005-05-03 2006-04-28 Forma cristalina de 1-cloro-4-(b(beta)-d-glucopiranos-1-il)-2-(4-((s)-tetrahidrofuran-3-iloxi)-bencil)-benceno, un método para su preparación y el uso del mismo para preparar medicamentos. UY29505A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05009669 2005-05-03
EP05018012 2005-08-19

Publications (1)

Publication Number Publication Date
UY29505A1 true UY29505A1 (es) 2006-11-30

Family

ID=36593171

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29505A UY29505A1 (es) 2005-05-03 2006-04-28 Forma cristalina de 1-cloro-4-(b(beta)-d-glucopiranos-1-il)-2-(4-((s)-tetrahidrofuran-3-iloxi)-bencil)-benceno, un método para su preparación y el uso del mismo para preparar medicamentos.

Country Status (33)

Country Link
US (2) US7713938B2 (es)
EP (2) EP2166007A1 (es)
JP (2) JP4226070B2 (es)
KR (1) KR101249711B1 (es)
CN (1) CN101155794B (es)
AR (2) AR053720A1 (es)
AT (1) ATE452883T1 (es)
AU (1) AU2006243859B8 (es)
BR (1) BRPI0610994B8 (es)
CA (1) CA2606650C (es)
CY (1) CY1109870T1 (es)
DE (1) DE602006011310D1 (es)
DK (1) DK1888552T3 (es)
EA (1) EA013079B1 (es)
ES (1) ES2337498T3 (es)
HK (1) HK1115133A1 (es)
HR (1) HRP20100033T1 (es)
IL (1) IL187087A (es)
ME (1) ME01173B (es)
MX (1) MX2007013144A (es)
MY (1) MY142108A (es)
NO (1) NO339073B1 (es)
NZ (1) NZ563563A (es)
PE (2) PE20091063A1 (es)
PL (1) PL1888552T3 (es)
PT (1) PT1888552E (es)
RS (1) RS51216B (es)
SI (1) SI1888552T1 (es)
TW (1) TWI344465B (es)
UA (1) UA91546C2 (es)
UY (1) UY29505A1 (es)
WO (1) WO2006117359A1 (es)
ZA (1) ZA200705883B (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7727987B2 (en) * 2003-11-17 2010-06-01 Merck Eprova Ag Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
EA011158B1 (ru) * 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
EP1776365B1 (en) * 2004-06-02 2011-08-03 Sandoz Ag Meropenem intermediate in crystalline form
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7687469B2 (en) * 2004-12-16 2010-03-30 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ATE445608T1 (de) * 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
WO2006108842A1 (en) * 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007004230A2 (en) * 2005-07-05 2007-01-11 Hetero Drugs Limited A novel process for the preparation of didanosine using novel intermediates
JP5128474B2 (ja) * 2005-07-27 2013-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
WO2007025943A2 (en) * 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US8507450B2 (en) 2005-09-08 2013-08-13 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) * 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
EA018698B1 (ru) * 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
NZ567357A (en) * 2005-10-31 2011-05-27 Janssen Pharmaceutica Nv Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
KR20080102395A (ko) * 2006-02-15 2008-11-25 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
JP5384343B2 (ja) * 2006-08-15 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
US7858587B2 (en) * 2006-09-21 2010-12-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
EP2615091B1 (en) * 2006-10-27 2016-01-20 Signal Pharmaceuticals, LLC Solid forms comprising 4-[9-(3S)-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-trans-cyclohexan-1-ol, compositions thereof, and uses therewith
CA2667550A1 (en) * 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
EP2079753A1 (en) 2006-11-06 2009-07-22 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2673498C (en) 2006-12-21 2012-04-24 Astellas Pharma Inc. Method for producing c-glycoside derivative and intermediate for synthesis thereof
CA2679310A1 (en) 2007-02-21 2008-08-28 Boehringer Ingelheim International Gmbh Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PL2187742T3 (pl) * 2007-08-23 2018-06-29 Theracos Sub, Llc Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy
WO2009068617A1 (en) * 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
MX2010007426A (es) * 2008-01-31 2010-08-18 Astellas Pharma Inc Composiciones farmaceuticas para tratar trastorno del higado graso.
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AR073118A1 (es) * 2008-08-22 2010-10-13 Theracos Inc Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo.
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2016213789B2 (en) * 2009-02-13 2018-01-18 Boehringer Ingelheim International Gmbh SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CN102316875A (zh) * 2009-02-13 2012-01-11 贝林格尔.英格海姆国际有限公司 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
NZ594024A (en) * 2009-02-13 2013-08-30 Boehringer Ingelheim Int Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
AU2010212867B2 (en) 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
AU2014200258B2 (en) * 2009-02-13 2016-05-12 Boehringer Ingelheim International Gmbh SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
JP5542196B2 (ja) * 2009-03-31 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−複素環−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａモジュレーターとしてのそれらの使用
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
EP2483286B1 (en) * 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
JP5758900B2 (ja) * 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
ES2742195T3 (es) 2010-03-12 2020-02-13 Omeros Corp Inhibidores de PDE10 y composiciones y métodos relacionados
EP2552442A1 (en) * 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
PE20130602A1 (es) 2010-08-12 2013-05-25 Boehringer Ingelheim Int Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
CA2808904A1 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AR085689A1 (es) * 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2012163990A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9174973B2 (en) * 2011-09-30 2015-11-03 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CN104427985A (zh) 2012-05-09 2015-03-18 勃林格殷格翰国际有限公司 用于治疗代谢性疾病的药物组合
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) * 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh) * 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN111494357A (zh) 2013-12-17 2020-08-07 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
WO2015101916A1 (en) 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Process for the preparation of empagliflozin
MX2016009421A (es) * 2014-01-23 2016-09-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales caninos.
HUE050095T2 (hu) 2014-04-01 2020-11-30 Boehringer Ingelheim Vetmedica Gmbh Anyagcsere-rendellenességek kezelése lófélékben
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
CN105384730A (zh) * 2014-09-03 2016-03-09 杭州普晒医药科技有限公司 依帕列净的晶型及其制备方法、药物组合物和用途
CN105481843A (zh) * 2014-09-19 2016-04-13 重庆医药工业研究院有限责任公司 一种恩格列净无定型物及其制备方法
EP3197429A1 (en) 2014-09-25 2017-08-02 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
EP3201191A1 (en) 2014-10-01 2017-08-09 Mylan Laboratories Ltd. Complex of amorphous empagliflozin and a cyclodextrin
CZ2015110A3 (cs) 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN107530313A (zh) 2015-04-24 2018-01-02 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
CZ2015279A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Pevné formy amorfního empagliflozinu
CN104788438B (zh) * 2015-05-04 2018-02-02 南京华威医药科技集团有限公司 恩格列净b晶型及其制备
CN106317035A (zh) * 2015-06-23 2017-01-11 中美华世通生物医药科技（武汉）有限公司 恩格列净单晶及其制备方法和用途
EP3341024A1 (en) 2015-08-27 2018-07-04 Boehringer Ingelheim Vetmedica GmbH Liquid pharmaceutical compositions comprising sglt-2 inhibitors
JP2018530592A (ja) 2015-10-15 2018-10-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
WO2017141202A1 (en) * 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
JP7161405B2 (ja) * 2016-03-16 2022-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エンパグリフロジンを含む医薬組成物及びその使用
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
HUE055463T2 (hu) 2016-10-13 2021-11-29 Boehringer Ingelheim Int Eljárás glükopiranozil-szubsztituált benzil-benzol-származékok elõállítására
WO2018073154A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
BR112019008384A2 (pt) 2016-11-10 2019-07-09 Boehringer Ingelheim Int composição farmacêutica, processos para tratamento e seus usos
WO2018163194A1 (en) * 2017-03-10 2018-09-13 Msn Laboratories Private Limited, R&D Center A process for the preparation of d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4- [[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, ( 1 s)
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性***PPARγ激动剂
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
CZ2018188A3 (cs) 2018-04-18 2019-10-30 Zentiva, K.S. Částice s obsahem amorfního empagliflozinu, způsob jejich přípravy a farmaceutický přípravek
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
JP2021532191A (ja) 2018-07-25 2021-11-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルポート症候群の治療に使用するためのエンパグリフロジン
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2020058095A1 (en) 2018-09-19 2020-03-26 Galenicum Health S.L.U. Pharmaceutical compositions of empagliflozin
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用
EP4076402A1 (en) 2019-12-19 2022-10-26 KRKA, d.d., Novo mesto Dosage form comprising amorphous solid solution of empagliflozin with polymer
KR102111248B1 (ko) 2019-12-30 2020-05-14 유니셀랩 주식회사 새로운 엠파글리플로진의 공결정
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
MX2022010748A (es) 2020-03-06 2022-09-23 Vertex Pharma Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种***共晶物及其制备方法和用途
KR102207319B1 (ko) 2020-03-23 2021-01-25 유니셀랩 주식회사 새로운 엠파글리플로진의 공결정
KR102150825B1 (ko) 2020-04-06 2020-09-03 유니셀랩 주식회사 새로운 sglt-2 억제제의 신규한 공결정
CN115397434A (zh) 2020-04-07 2022-11-25 勃林格殷格翰国际有限公司 治疗头痛障碍的方法
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
WO2021250565A1 (en) * 2020-06-10 2021-12-16 Hikal Limited An improved process for preparation of empagliflozin and its crystalline polymorph
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
KR102218323B1 (ko) 2020-09-09 2021-02-22 유니셀랩 주식회사 효율적이고 상전이가 되지 않는 엠파글리플로진 무정형의 제조방법
KR20220080880A (ko) 2020-12-08 2022-06-15 주식회사 종근당 엠파글리플로진 공결정을 함유하는 약제학적 조성물
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
EP4299055A1 (en) 2022-06-29 2024-01-03 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral dosage formulations comprising empagliflozin
EP4342459A1 (en) 2022-09-20 2024-03-27 Galenicum Health S.L.U. Pharmaceutical compositions of empagliflozin

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
NL167151C (nl) * 1971-04-09 1981-11-16 Acf Chemiefarma Nv Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen.
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2951135A1 (de) * 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS58164502A (ja) 1982-03-26 1983-09-29 Chugai Pharmaceut Co Ltd 除草用組成物
US4786755A (en) * 1985-06-03 1988-11-22 Warner-Lambert Company Diphenic acid monoamides
US4602023A (en) 1985-06-03 1986-07-22 Warner-Lambert Company Diphenic acid monoamides
US4786023A (en) * 1987-08-19 1988-11-22 Harris Leverett D Drafting implement holder
AU6024998A (en) 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
JPH11124392A (ja) 1997-10-21 1999-05-11 Sankyo Co Ltd Ｃ−グリコシル化されたアリールスズ化合物
US6613806B1 (en) * 1999-01-29 2003-09-02 Basf Corporation Enhancement of the efficacy of benzoylbenzenes
PL203124B1 (pl) * 1999-08-31 2009-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna je zawierająca i związki pośrednie
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
SI1329456T1 (sl) 2000-09-29 2006-12-31 Kissei Pharmaceutical Glukopiranoziloksibenzilbenzenski derivati in zdravilni sestavki, ki vsebujejo te spojine
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP3698067B2 (ja) * 2001-03-30 2005-09-21 Ｊｓｒ株式会社 電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜
CA2444481A1 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
US6744112B2 (en) * 2002-10-01 2004-06-01 International Business Machines Corporation Multiple chip guard rings for integrated circuit and chip guard ring interconnect
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
BR0317929A (pt) 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
EP1597266A4 (en) 2003-02-27 2008-02-20 Bristol Myers Squibb Co NON-CRYOGENIC PROCESS FOR THE PRODUCTION OF GLYCOSIDES
US7202350B2 (en) * 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
US7772192B2 (en) * 2003-06-03 2010-08-10 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
EA009768B1 (ru) 2003-08-01 2008-04-28 Янссен Фармацевтика Нв Замещенные конденсированные гетероциклические с-гликозиды
AR045173A1 (es) 2003-08-01 2005-10-19 Tanabe Seiyaku Co Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
CA2539032A1 (en) 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
US7375090B2 (en) * 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US20050085680A1 (en) * 2003-10-21 2005-04-21 Joseph Auerbach Method for industrial decontamination
US7371732B2 (en) * 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
BRPI0508259A (pt) 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
US7732596B2 (en) 2004-03-04 2010-06-08 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
EA011158B1 (ru) * 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
US7393836B2 (en) * 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) * 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7687469B2 (en) 2004-12-16 2010-03-30 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ATE445608T1 (de) 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
WO2006108842A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
JP5128474B2 (ja) 2005-07-27 2013-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
WO2007025943A2 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US8507450B2 (en) 2005-09-08 2013-08-13 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
KR20080102395A (ko) 2006-02-15 2008-11-25 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5384343B2 (ja) * 2006-08-15 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
US7858587B2 (en) * 2006-09-21 2010-12-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
CA2667550A1 (en) * 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
EP2079753A1 (en) * 2006-11-06 2009-07-22 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
JP5337040B2 (ja) * 2006-11-09 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ−２インヒビターとの組み合わせ治療及びそれらの医薬組成物
CL2008000224A1 (es) * 2007-01-26 2008-05-23 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
CA2679310A1 (en) * 2007-02-21 2008-08-28 Boehringer Ingelheim International Gmbh Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101754972A (zh) * 2007-05-18 2010-06-23 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CN102316875A (zh) * 2009-02-13 2012-01-11 贝林格尔.英格海姆国际有限公司 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
AU2010212867B2 (en) * 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
NZ594024A (en) * 2009-02-13 2013-08-30 Boehringer Ingelheim Int Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
JP5758900B2 (ja) * 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
EP2483286B1 (en) * 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof

Also Published As

Publication number Publication date
AU2006243859B2 (en) 2011-09-29
CA2606650A1 (en) 2006-11-09
EA200702346A1 (ru) 2008-04-28
UA91546C2 (uk) 2010-08-10
TW200716586A (en) 2007-05-01
AU2006243859A1 (en) 2006-11-09
KR101249711B1 (ko) 2013-04-05
JP2009046513A (ja) 2009-03-05
JP4226070B2 (ja) 2009-02-18
KR20080015424A (ko) 2008-02-19
SI1888552T1 (sl) 2010-04-30
ATE452883T1 (de) 2010-01-15
NO339073B1 (no) 2016-11-07
CN101155794B (zh) 2011-05-11
CA2606650C (en) 2014-02-11
PE20061374A1 (es) 2007-01-09
DE602006011310D1 (de) 2010-02-04
BRPI0610994A2 (pt) 2010-08-10
WO2006117359A1 (en) 2006-11-09
MY142108A (en) 2010-09-15
ME01173B (me) 2013-03-20
TWI344465B (en) 2011-07-01
US20100099641A1 (en) 2010-04-22
PT1888552E (pt) 2010-03-02
JP2008540373A (ja) 2008-11-20
HK1115133A1 (es) 2008-11-21
EP2166007A1 (en) 2010-03-24
AR053720A1 (es) 2007-05-16
NZ563563A (en) 2010-11-26
BRPI0610994B1 (pt) 2020-08-25
BRPI0610994B8 (pt) 2021-05-25
CY1109870T1 (el) 2014-09-10
EP1888552A1 (en) 2008-02-20
MX2007013144A (es) 2008-01-21
PE20091063A1 (es) 2009-08-19
AU2006243859B8 (en) 2011-11-10
ES2337498T3 (es) 2010-04-26
CN101155794A (zh) 2008-04-02
ZA200705883B (en) 2008-09-25
US20070249544A1 (en) 2007-10-25
IL187087A0 (en) 2008-02-09
PL1888552T3 (pl) 2010-06-30
DK1888552T3 (da) 2010-04-12
AR087208A2 (es) 2014-02-26
RS51216B (sr) 2010-12-31
NO20073875L (no) 2007-10-18
HRP20100033T1 (hr) 2010-03-31
EA013079B1 (ru) 2010-02-26
EP1888552B1 (en) 2009-12-23
US7713938B2 (en) 2010-05-11
IL187087A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
UY29505A1 (es) Forma cristalina de 1-cloro-4-(b(beta)-d-glucopiranos-1-il)-2-(4-((s)-tetrahidrofuran-3-iloxi)-bencil)-benceno, un método para su preparación y el uso del mismo para preparar medicamentos.
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
AR107510A2 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO Y PROCESO PARA LA PREPARACIÓN
EA201200506A1 (ru) СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ)БЕНЗОЛА
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
BRPI0822722A2 (pt) Implemento para cuidado oral.
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
DE602006012665D1 (de) Kristalline formen von 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-ä4-((r)-tetrahydrofuran-3-yloxy)-benzylü-benzol, zubereitungsverfahren dafür und dessen verwendung zur arzneimittelherstellung
CL2013001723A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico.
BR112012003287A2 (pt) implemento para cuidado oral.
UY31136A1 (es) Oxazolidinonas sustituidas y su uso
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
BRPI0813438A2 (pt) Processo para preparar um composto, uso de um composto, e, composto.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
CL2012001290A1 (es) Compuestos derivados de canfenos arilados, estimulantes selectivos de receptores cb2; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad, trastorno o afeccion seleccionada de inflamacion, dolor, alergia, diabetes, ateroesclerosis, artritis y emesis, entre otras.
BRPI0814576A2 (pt) Item de calçado, e, métodos para preparar um item de calçado, e para aperfeiçoar o conforto de um item de calçado para o usuário.
CL2013002052A1 (es) Uso de quitosanos para aumentar el ritmo de crecimiento de la uña (divisional de la sol. 444-08).
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0921302A2 (pt) clínquer, processos para fabricar um clínquer e para reduzir a aptidão de um clínquer à produção de poeira, produto e utilização de um produto.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
BRPI0920878A2 (pt) inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200624